Drug Search Results
More Filters [+]

BR-6002

Alternative Names: BR-6002, BR 6002, BR6002
Latest Update: 2023-11-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boryung
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BR-6002

Countries in Clinic: Korea

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Duodenal Ulcer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BR-ARC-CT-103

P1

Completed

Duodenal Ulcer

2023-09-12

21%

BR-ARC-CT-102

P1

Completed

Duodenal Ulcer

2023-08-24

21%

Recent News Events

Date

Type

Title